Brief: Argenx Announces European Commission Approval Of Vyvgart Subcutaneous Injection
20/06/2025 18:01
June 20 (Reuters) - argenx SE ARGX.BR: ARGENX ANNOUNCES EUROPEAN COMMISSION APPROVAL OF VYVGART SUBCUTANEOUS INJECTION FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY EC APPROVES VYVGART SC FOR CIDP IN EUROPE FIRST NOVEL MECHANISM OF ACTION FOR CIDP IN 30 YEARS EC APPROVES VYVGART 1000MG SC INJECTION FOR CIDP EC APPROVAL APPLIES TO EU, ICELAND, LIECHTENSTEIN, NORWAY Source text: nGNXbB5bzc Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles